Pacira BioSciences (PCRX) Financials

$25.75 -0.32 (-1.23%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$25.77 +0.02 (+0.08%)

As of 05/23/2025 04:20 PM Eastern

Annual Income Statements for Pacira BioSciences

This table shows Pacira BioSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Income / (Loss) Attributable to Common Shareholders	-404	9.34	-15	42	146	-11	-0.47	-43	-38	1.86	-14
Consolidated Net Income / (Loss)	-199	84	32	42	146	-11	-0.47	-43	-38	1.86	-14
Net Income / (Loss) Continuing Operations	-404	9.34	-15	42	146	-11	-0.47	-43	-38	1.86	-14
Total Pre-Tax Income	-126	123	27	56	20	-11	-0.43	-42	-38	2.12	-14
Total Operating Income	-73	88	60	90	46	10	16	-25	-32	9.46	-5.17
Total Gross Profit	1,232	1,165	1,134	401	312	314	250	199	166	177	120
Total Revenue	1,402	1,350	1,334	542	430	421	337	287	276	249	198
Operating Revenue	1,402	1,350	1,334	542	430	421	337	287	276	249	198
Total Cost of Revenue	170	185	199	140	117	107	87	88	110	72	77
Operating Cost of Revenue	170	185	199	140	117	107	87	88	110	72	77
Total Operating Expenses	1,591	1,048	1,061	311	266	304	235	224	198	168	125
Selling, General & Admin Expense	294	269	255	199	194	201	177	161	153	139	107
Research & Development Expense	82	76	85	56	59	72	56	57	46	29	19
Amortization Expense	115	115	115	14	7.87	5.70	0.00	0.00	-	-	-
Other Operating Expenses / (Income)	774	587	607	43	-	-	-	-	0.00	0.00	-
Impairment Charge	326	0.00	0.00	-	5.17	-	-	-	-	-	-
Total Other Income / (Expense), net	28	-69	-93	-34	-26	-21	-16	-18	-5.82	-7.34	-8.38
Interest Expense	1.53	54	40	32	34	24	22	22	7.06	7.78	8.28
Interest & Investment Income	20	11	4.54	0.90	4.63	7.38	6.50	4.08	1.32	0.68	0.38
Other Income / (Expense), net	9.89	-26	-58	-2.67	2.85	-4.98	-0.89	0.17	-0.08	-0.24	-0.48
Income Tax Expense	73	39	-5.21	14	-125	0.27	0.05	0.14	0.11	0.26	0.17
Basic Earnings per Share	($2.15)	$0.91	$0.35	$0.95	$3.41	($0.27)	($0.01)	($1.07)	($1.02)	$0.05	($0.39)
Weighted Average Basic Shares Outstanding	46.25M	46.22M	45.52M	44.26M	42.67M	41.51M	40.91M	39.81M	37.24M	36.54M	35.30M
Diluted Earnings per Share	($2.15)	$0.89	$0.34	$0.92	$3.33	($0.27)	($0.01)	($1.07)	($1.02)	$0.04	($0.39)
Weighted Average Diluted Shares Outstanding	46.25M	51.98M	46.54M	45.63M	43.68M	41.51M	40.91M	39.81M	37.24M	41.30M	35.30M
Weighted Average Basic & Diluted Shares Outstanding	46.28M	46.50M	45.95M	44.85M	43.86M	41.51M	40.91M	39.81M	37.24M	37.10M	35.30M

This table shows Pacira BioSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	4.81	-289	-143	19	8.98	-7.74	11	26	-20	-41	-0.69
Consolidated Net Income / (Loss)	4.81	-84	-143	19	8.98	67	11	26	-20	5.81	-0.69
Net Income / (Loss) Continuing Operations	4.81	-289	-143	19	8.98	-7.74	11	26	-20	-41	-0.69
Total Pre-Tax Income	8.71	-38	-139	37	14	95	17	38	-26	-4.77	2.07
Total Operating Income	1.99	25	-140	28	13	33	18	40	-3.09	-9.89	21
Total Gross Profit	135	848	130	134	120	809	124	121	111	777	117
Total Revenue	169	888	169	178	167	856	164	169	160	839	167
Operating Revenue	169	888	169	178	167	856	164	169	160	839	167
Total Cost of Revenue	34	40	39	44	47	48	40	48	49	62	51
Operating Cost of Revenue	34	40	39	44	47	48	40	48	49	62	51
Total Operating Expenses	133	1,110	269	106	106	745	106	81	114	773	95
Selling, General & Admin Expense	87	80	74	68	72	66	68	65	71	64	61
Research & Development Expense	25	24	19	20	18	19	21	19	17	18	19
Amortization Expense	14	72	14	14	14	72	14	14	14	72	14
Restructuring Charge	6.19	-	-	2.74	1.90	-	-	-	12	-	0.49
Total Other Income / (Expense), net	6.72	19	0.67	8.34	0.43	-42	-1.12	-2.02	-23	-55	-19
Interest Expense	4.58	-2.84	4.69	-3.63	3.32	20	3.46	3.87	27	11	9.86
Interest & Investment Income	6.90	5.56	5.48	4.75	3.90	3.43	2.77	2.11	3.14	2.79	1.23
Other Income / (Expense), net	4.40	10	-0.12	-0.04	-0.16	-25	-0.42	-0.27	-0.01	-47	-11
Income Tax Expense	3.89	46	4.61	18	4.66	29	5.74	12	-6.94	-11	2.76
Basic Earnings per Share	$0.10	$0.36	($3.11)	$0.41	$0.19	$0.55	$0.23	$0.56	($0.43)	($0.22)	($0.02)
Weighted Average Basic Shares Outstanding	46.28M	46.25M	46.13M	46.17M	46.50M	46.22M	46.42M	46.09M	45.95M	45.52M	45.83M
Diluted Earnings per Share	$0.10	$0.38	($3.11)	$0.39	$0.19	$0.58	$0.23	$0.51	($0.43)	($0.19)	($0.02)
Weighted Average Diluted Shares Outstanding	46.53M	46.25M	46.13M	50.54M	52.19M	51.98M	52.07M	52.05M	45.95M	46.54M	45.83M
Weighted Average Basic & Diluted Shares Outstanding	46.30M	46.28M	46.17M	46.13M	46.55M	46.50M	46.44M	46.42M	45.99M	45.95M	-

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Net Change in Cash & Equivalents	123	49	-481	486	22	-54	78	18	-21	19	25
Net Cash From Operating Activities	189	155	145	126	77	71	49	18	33	28	27
Net Cash From Continuing Operating Activities	189	155	145	126	77	71	49	18	33	28	27
Net Income / (Loss) Continuing Operations	-100	42	16	42	146	-11	-0.47	-43	-38	1.86	-14
Consolidated Net Income / (Loss)	-100	42	16	42	146	-11	-0.47	-43	-38	1.86	-14
Depreciation Expense	79	76	92	29	20	20	13	14	13	11	10
Amortization Expense	3.22	3.75	7.21	26	18	15	13	12	4.57	4.58	4.63
Non-Cash Adjustments To Reconcile Net Income	209	67	85	45	41	39	34	37	32	33	25
Changes in Operating Assets and Liabilities, net	-2.36	-34	-54	-16	-147	7.90	-11	-2.57	22	-23	0.64
Net Cash From Investing Activities	-83	78	-225	-21	-278	-128	21	-224	-62	-19	-120
Net Cash From Continuing Investing Activities	-83	78	-225	-21	-278	-128	21	-224	-62	-19	-120
Purchase of Property, Plant & Equipment	-11	-15	-30	-46	-38	-10	-15	-19	-25	-40	-23
Purchase of Investments	-252	-144	-401	-629	-548	-320	-363	-503	-193	-189	-164
Sale and/or Maturity of Investments	180	237	238	1,078	308	319	405	322	172	217	80
Other Investing Activities, net	0.00	0.00	-32	-4.00	0.00	0.00	-6.84	-8.46	-16	-7.12	-13
Net Cash From Financing Activities	17	-183	-402	381	222	3.67	8.95	224	7.26	11	119
Net Cash From Continuing Financing Activities	17	-183	-402	381	222	3.67	8.95	224	7.26	11	119
Repayment of Debt	-211	-336	-428	0.00	-189	-0.34	0.00	-129	0.00	-1.47	0.00
Repurchase of Common Equity	-34	-1.16	-1.18	-4.55	-	-	-	-	-	-	-
Issuance of Debt	288	150	0.00	364	369	0.00	0.00	345	0.00	0.00	0.00
Issuance of Common Equity	2.30	2.81	2.95	2.81	2.55	2.40	1.78	1.86	1.50	2.09	112
Other Financing Activities, net	-27	1.83	24	19	40	1.61	7.17	6.49	5.77	10	7.24
Cash Interest Paid	15	28	33	7.00	7.21	8.20	8.21	6.90	3.85	4.22	5.19
Cash Income Taxes Paid	11	4.37	7.40	3.22	2.42	0.86	0.13	0.13	0.25	0.20	0.03

This table details how cash moves in and out of Pacira BioSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	6.84	31	-1.09	63	31	54	12	51	-69	-5.29	-13
Net Cash From Operating Activities	35	33	54	53	49	48	44	43	19	42	43
Net Cash From Continuing Operating Activities	35	33	54	53	49	48	44	43	19	42	43
Net Income / (Loss) Continuing Operations	4.81	16	-143	19	8.98	25	11	26	-20	-10	-0.69
Consolidated Net Income / (Loss)	4.81	16	-143	19	8.98	25	11	26	-20	-10	-0.69
Depreciation Expense	21	21	20	19	18	18	18	19	20	30	20
Amortization Expense	0.87	0.87	0.86	0.79	0.71	0.71	0.71	0.72	1.61	2.14	1.60
Non-Cash Adjustments To Reconcile Net Income	8.67	15	176	5.04	13	12	15	11	29	39	23
Changes in Operating Assets and Liabilities, net	-0.05	-20	-0.04	9.66	7.77	-8.62	-0.50	-13	-11	-19	-1.21
Net Cash From Investing Activities	-26	-0.37	-52	-15	-16	8.37	-4.34	7.33	66	11	-48
Net Cash From Continuing Investing Activities	-26	-0.37	-52	-15	-16	8.37	-4.34	7.33	66	11	-48
Purchase of Property, Plant & Equipment	-8.55	-2.12	-4.09	-1.59	-2.84	-1.80	-3.39	-3.40	-6.57	-5.49	-5.18
Acquisitions	-17	-	-	-	-	-	-	-	-	-	-
Purchase of Investments	-70	-45	-101	-50	-56	-26	-42	-23	-53	-68	-132
Sale and/or Maturity of Investments	69	47	53	36	43	36	41	34	126	85	90
Net Cash From Financing Activities	-2.99	-1.96	-2.85	25	-2.82	-1.78	-28	0.44	-154	-59	-7.78
Net Cash From Continuing Financing Activities	-2.99	-1.96	-2.85	25	-2.82	-1.78	-28	0.44	-154	-59	-7.78
Repayment of Debt	-2.81	-2.81	-2.81	-202	-2.81	-2.81	-28	-2.81	-303	-59	-9.38
Other Financing Activities, net	-0.18	-0.08	-0.03	-27	-0.00	-0.11	0.03	1.58	0.33	0.91	1.60
Cash Interest Paid	2.72	5.23	3.20	3.02	3.97	2.70	4.13	3.17	18	9.68	8.93
Cash Income Taxes Paid	0.29	1.45	4.91	4.91	-0.25	2.29	1.28	0.59	0.20	3.18	0.11

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Assets	1,554	1,574	1,681	2,075	1,275	831	689	628	391	388	326
Total Current Assets	745	510	498	866	652	409	478	391	243	253	214
Cash & Equivalents	277	153	104	586	100	78	133	54	36	57	38
Short-Term Investments	208	125	185	71	422	214	251	257	137	102	119
Accounts Receivable	113	106	98	96	53	48	38	32	30	26	22
Inventories, net	125	104	96	99	65	58	49	41	31	62	29
Prepaid Expenses	22	22	15	15	12	11	7.95	6.69	9.28	6.12	4.46
Plant, Property, & Equipment, net	167	174	184	188	137	105	109	107	101	90	61
Total Noncurrent Assets	641	890	999	1,021	486	318	103	130	47	45	51
Long-Term Investments	36	38	64	22	95	65	41	74	0.00	13	24
Goodwill	0.00	163	163	145	100	100	62	55	47	31	24
Intangible Assets	426	483	541	624	97	104	0.00	-	-	0.08	0.40
Noncurrent Deferred & Refundable Income Taxes	130	144	160	153	106	0.00	-	-	-	-	-
Other Noncurrent Operating Assets	49	61	71	76	89	49	0.00	0.83	0.62	0.41	2.59
Total Liabilities & Shareholders' Equity	1,554	1,574	1,681	2,075	1,275	831	689	628	391	388	326
Total Liabilities	775	704	906	1,345	655	476	368	349	172	169	155
Total Current Liabilities	310	97	148	521	253	108	61	56	45	150	140
Short-Term Debt	202	8.64	34	375	150	0.00	0.34	0.32	0.00	104	103
Accounts Payable	19	16	15	11	10	13	14	15	7.51	8.74	6.76
Accrued Expenses	80	64	90	128	71	70	46	41	37	35	28
Other Current Liabilities	8.89	8.80	9.12	7.89	22	23	0.00	-	-	-	0.28
Total Noncurrent Liabilities	465	607	758	824	401	368	307	293	128	20	15
Long-Term Debt	384	514	656	675	313	306	291	276	109	0.00	-
Other Noncurrent Operating Liabilities	82	93	103	149	88	62	17	16	19	11	5.41
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	778	870	775	730	620	355	321	279	219	218	171
Total Preferred & Common Equity	778	870	775	730	620	355	321	279	219	218	171
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	778	870	775	730	620	355	321	279	219	218	171
Common Stock	1,009	977	924	942	873	754	710	669	565	527	481
Retained Earnings	-206	-107	-149	-212	-254	-399	-388	-389	-346	-308	-310
Treasury Stock	-25	0.00	-	-	-	-	-	-	-	-	-
Accumulated Other Comprehensive Income / (Loss)	0.34	0.25	-0.38	0.17	0.32	0.32	-0.28	-0.45	-0.03	-0.05	-0.08

This table presents Pacira BioSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023
Total Assets	1,587	1,522	1,647	1,583	1,534	1,542	1,523
Total Current Assets	760	690	632	543	447	429	376
Cash & Equivalents	284	246	247	184	99	87	36
Short-Term Investments	210	208	157	142	136	134	138
Accounts Receivable	105	101	105	102	97	99	93
Inventories, net	134	112	103	97	97	92	93
Prepaid Expenses	28	24	20	19	19	17	16
Plant, Property, & Equipment, net	164	167	169	172	176	180	182
Total Noncurrent Assets	662	665	846	868	911	933	966
Long-Term Investments	28	37	36	37	36	36	8.28
Goodwill	22	0.00	163	163	163	163	163
Intangible Assets	435	440	455	469	498	512	526
Noncurrent Deferred & Refundable Income Taxes	129	134	135	141	152	156	168
Other Noncurrent Operating Assets	49	54	56	59	63	66	100
Total Liabilities & Shareholders' Equity	1,587	1,522	1,647	1,583	1,534	1,542	1,523
Total Liabilities	788	772	768	691	703	734	755
Total Current Liabilities	315	306	93	93	94	109	99
Short-Term Debt	202	201	0.00	8.64	8.64	20	11
Accounts Payable	23	19	19	8.98	17	24	17
Accrued Expenses	80	76	65	67	60	56	62
Other Current Liabilities	9.41	9.19	9.15	9.00	8.63	8.98	8.95
Total Noncurrent Liabilities	473	466	675	598	609	625	657
Long-Term Debt	381	386	589	512	516	532	543
Noncurrent Deferred & Payable Income Tax Liabilities	7.00	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	85	80	86	86	93	93	114
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	799	750	879	892	832	808	768
Total Preferred & Common Equity	799	750	879	892	832	808	768
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	799	750	879	892	832	808	768
Common Stock	1,024	996	983	990	963	951	936
Retained Earnings	-202	-222	-79	-98	-132	-143	-168
Treasury Stock	-25	-25	-25	-	-	-	-
Accumulated Other Comprehensive Income / (Loss)	1.35	0.68	0.11	0.15	-0.01	-0.17	-0.14

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.85%	1.22%	146.27%	26.04%	2.05%	24.83%	17.67%	3.71%	10.99%	25.97%	131.05%
EBITDA Growth	-86.84%	39.83%	-28.92%	62.21%	115.54%	-1.12%	5,484.60%	105.02%	-157.84%	180.42%	120.58%
EBIT Growth	-203.19%	2,954.37%	-97.69%	77.35%	793.93%	-63.37%	160.67%	22.85%	-448.26%	263.25%	89.53%
NOPAT Growth	-186.15%	-16.95%	7.26%	-80.07%	4,476.82%	-34.15%	163.82%	22.13%	-370.81%	328.95%	90.31%
Net Income Growth	-337.30%	163.72%	-24.21%	-71.15%	1,421.01%	-2,238.85%	98.89%	-12.28%	-2,144.67%	113.53%	78.54%
EPS Growth	-341.57%	161.76%	-63.04%	-72.37%	1,333.33%	-2,600.00%	99.07%	-4.90%	-2,650.00%	110.26%	79.79%
Operating Cash Flow Growth	22.46%	6.45%	15.56%	63.20%	9.23%	44.30%	174.78%	-46.84%	19.39%	5.48%	160.60%
Free Cash Flow Firm Growth	89.20%	55.15%	110.82%	-425.64%	260.50%	-1,588.67%	80.33%	-19.07%	45.03%	-73.66%	47.81%
Invested Capital Growth	-21.58%	-3.23%	0.93%	136.70%	52.92%	61.81%	10.32%	9.88%	3.41%	63.68%	37.97%
Revenue Q/Q Growth	101.73%	102.79%	0.00%	5.50%	2.03%	6.94%	4.99%	2.20%	1.31%	3.12%	16.66%
EBITDA Q/Q Growth	28.86%	3.05%	0.00%	-4.35%	26.57%	-17.14%	7.00%	105.67%	-11.42%	-24.91%	190.52%
EBIT Q/Q Growth	1.91%	39.83%	0.00%	-14.60%	59.09%	-67.21%	31.61%	30.75%	-5.38%	-48.78%	76.08%
NOPAT Q/Q Growth	-13.04%	89.70%	0.00%	-21.74%	-64.95%	-81.95%	31.34%	30.47%	-5.43%	-52.05%	77.45%
Net Income Q/Q Growth	-119.46%	1,101.63%	0.00%	-31.88%	15.38%	-610.71%	88.68%	16.74%	-4.04%	-81.73%	56.42%
EPS Q/Q Growth	-10.26%	641.67%	0.00%	-34.75%	16.84%	-640.00%	88.89%	18.94%	-5.15%	-85.71%	57.61%
Operating Cash Flow Q/Q Growth	-7.09%	3.72%	0.00%	-15.72%	36.90%	7.11%	9.62%	-2.30%	1.07%	8.82%	437.73%
Free Cash Flow Firm Q/Q Growth	-6.61%	109.06%	-87.85%	-1,397.82%	-77.98%	-51.46%	60.93%	-19.30%	14.73%	2.28%	14.84%
Invested Capital Q/Q Growth	-0.35%	-0.91%	0.00%	117.36%	0.06%	1.26%	0.05%	4.59%	-3.40%	0.30%	13.07%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.84%	86.32%	85.06%	74.10%	72.69%	74.65%	74.25%	69.33%	60.16%	71.15%	60.82%
EBITDA Margin	1.32%	10.43%	7.55%	26.17%	20.33%	9.63%	12.15%	0.26%	-5.29%	10.15%	4.56%
Operating Margin	-5.23%	6.49%	4.50%	16.61%	10.79%	2.49%	4.72%	-8.70%	-11.59%	3.80%	-2.61%
EBIT Margin	-4.53%	4.56%	0.15%	16.11%	11.45%	1.31%	4.46%	-8.64%	-11.62%	3.70%	-2.86%
Profit (Net Income) Margin	-14.20%	6.22%	2.39%	7.75%	33.87%	-2.62%	-0.14%	-14.87%	-13.73%	0.75%	-6.94%
Tax Burden Percent	157.77%	68.00%	119.60%	74.43%	724.39%	102.49%	110.82%	100.33%	100.28%	87.55%	101.28%
Interest Burden Percent	198.82%	200.60%	1,320.95%	64.64%	40.83%	-195.28%	-2.83%	171.46%	117.87%	23.00%	239.83%
Effective Tax Rate	0.00%	32.00%	-19.60%	25.57%	-624.39%	0.00%	0.00%	0.00%	0.00%	12.45%	0.00%
Return on Invested Capital (ROIC)	-5.35%	5.45%	6.49%	8.55%	87.27%	2.98%	6.22%	-10.72%	-14.69%	6.85%	-4.57%
ROIC Less NNEP Spread (ROIC-NNEP)	-114.62%	14.42%	-4.81%	-14.51%	272.73%	22.94%	15.80%	18.37%	8.80%	15.54%	32.61%
Return on Net Nonoperating Assets (RNNOA)	-18.81%	4.75%	-2.26%	-2.33%	-57.41%	-6.24%	-6.37%	-6.37%	-2.66%	-5.90%	-8.34%
Return on Equity (ROE)	-24.16%	10.20%	4.23%	6.22%	29.86%	-3.26%	-0.16%	-17.10%	-17.35%	0.95%	-12.92%
Cash Return on Invested Capital (CROIC)	18.84%	8.74%	5.57%	-72.66%	45.42%	-44.23%	-3.60%	-20.14%	-18.04%	-41.45%	-36.49%
Operating Return on Assets (OROA)	-4.06%	3.78%	0.11%	5.21%	4.67%	0.72%	2.28%	-4.86%	-8.24%	2.58%	-2.28%
Return on Assets (ROA)	-12.73%	5.15%	1.69%	2.51%	13.82%	-1.45%	-0.07%	-8.36%	-9.74%	0.52%	-5.53%
Return on Common Equity (ROCE)	-24.16%	10.20%	4.23%	6.22%	29.86%	-3.26%	-0.16%	-17.10%	-17.35%	0.95%	-12.92%
Return on Equity Simple (ROE_SIMPLE)	-25.58%	9.64%	4.11%	5.75%	23.48%	-3.10%	-0.15%	-15.25%	-17.33%	0.85%	-8.01%
Net Operating Profit after Tax (NOPAT)	-51	60	72	67	336	7.34	11	-17	-22	8.28	-3.62
NOPAT Margin	-3.66%	4.42%	5.38%	12.36%	78.15%	1.74%	3.30%	-6.09%	-8.11%	3.32%	-1.83%
Net Nonoperating Expense Percent (NNEP)	109.27%	-8.97%	11.30%	23.06%	-185.46%	-19.96%	-9.59%	-29.10%	-23.49%	-8.68%	-37.19%
Return On Investment Capital (ROIC_SIMPLE)	-3.77%	4.28%	4.90%	-	-	-	-	-	-	-	-
Cost of Revenue to Revenue	12.16%	13.68%	14.94%	25.90%	27.31%	25.35%	25.75%	30.67%	39.84%	28.85%	39.18%
SG&A Expenses to Revenue	20.98%	19.96%	19.08%	36.81%	45.04%	47.69%	52.56%	56.34%	55.22%	55.84%	53.96%
R&D to Revenue	5.82%	5.65%	6.36%	10.26%	13.83%	17.13%	16.51%	19.99%	16.53%	11.51%	9.48%
Operating Expenses to Revenue	113.49%	77.60%	79.53%	57.49%	61.90%	72.17%	69.53%	78.03%	71.75%	67.35%	63.44%
Earnings before Interest and Taxes (EBIT)	-63	62	2.01	87	49	5.50	15	-25	-32	9.22	-5.65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	19	141	101	142	87	41	41	0.73	-15	25	9.01
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.12	1.80	2.28	3.67	4.20	5.33	5.51	6.63	5.52	12.92	18.68
Price to Tangible Book Value (P/TBV)	2.47	7.01	24.84	0.00	6.14	12.52	6.82	8.26	7.01	15.06	21.75
Price to Revenue (P/Rev)	0.62	1.16	1.33	4.95	6.05	4.49	5.24	6.46	4.37	11.34	16.17
Price to Earnings (P/E)	0.00	167.68	0.00	63.85	17.86	0.00	0.00	0.00	0.00	1,520.80	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.60%	0.00%	1.57%	5.60%	0.00%	0.00%	0.00%	0.00%	0.07%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.11	1.65	1.89	2.77	5.26	6.05	8.70	10.23	7.38	18.36	34.01
Enterprise Value to Revenue (EV/Rev)	0.67	1.31	1.58	5.63	5.69	4.37	4.85	6.08	4.14	11.06	15.77
Enterprise Value to EBITDA (EV/EBITDA)	50.46	12.58	20.91	21.53	27.99	45.39	39.90	2,374.63	0.00	108.96	345.82
Enterprise Value to EBIT (EV/EBIT)	0.00	28.81	1,045.54	34.97	49.70	334.25	108.84	0.00	0.00	298.75	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	29.73	29.33	45.59	7.28	250.78	146.81	0.00	0.00	332.73	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	4.94	11.46	14.49	24.27	31.74	26.09	33.47	98.00	34.20	98.29	117.35
Enterprise Value to Free Cash Flow (EV/FCFF)	5.17	18.55	34.20	0.00	13.99	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.75	0.60	0.89	1.44	0.75	0.86	0.91	0.99	0.50	0.48	0.60
Long-Term Debt to Equity	0.49	0.59	0.85	0.92	0.51	0.86	0.90	0.99	0.50	0.00	0.00
Financial Leverage	0.16	0.33	0.47	0.16	-0.21	-0.27	-0.40	-0.35	-0.30	-0.38	-0.26
Leverage Ratio	1.90	1.98	2.50	2.48	2.16	2.25	2.19	2.05	1.78	1.83	2.33
Compound Leverage Factor	3.77	3.97	32.96	1.60	0.88	-4.39	-0.06	3.51	2.10	0.42	5.60
Debt to Total Capital	42.92%	37.52%	47.08%	58.96%	42.75%	46.30%	47.53%	49.73%	33.18%	32.27%	37.59%
Short-Term Debt to Total Capital	14.80%	0.62%	2.30%	21.05%	13.83%	0.00%	0.06%	0.06%	0.00%	32.27%	37.59%
Long-Term Debt to Total Capital	28.13%	36.90%	44.78%	37.90%	28.92%	46.30%	47.47%	49.67%	33.18%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	57.08%	62.48%	52.92%	41.04%	57.25%	53.70%	52.47%	50.27%	66.82%	67.73%	62.41%
Debt to EBITDA	31.59	3.71	6.85	7.40	5.30	7.55	7.10	376.70	-7.44	4.12	11.44
Net Debt to EBITDA	3.51	1.46	3.34	2.62	-1.77	-1.25	-3.25	-148.56	4.37	-2.71	-8.82
Long-Term Debt to EBITDA	20.70	3.65	6.51	4.76	3.58	7.55	7.09	376.26	-7.44	0.00	0.00
Debt to NOPAT	-11.40	8.76	9.60	15.68	1.38	41.72	26.11	-15.84	-4.85	12.57	-28.52
Net Debt to NOPAT	-1.27	3.45	4.69	5.54	-0.46	-6.91	-11.96	6.25	2.85	-8.26	21.99
Long-Term Debt to NOPAT	-7.47	8.62	9.14	10.08	0.93	41.72	26.08	-15.82	-4.85	0.00	0.00
Altman Z-Score	1.59	2.54	2.10	1.65	2.94	2.67	3.38	3.28	4.01	9.93	11.87
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.40	5.24	3.37	1.66	2.57	3.79	7.88	6.96	5.42	1.69	1.53
Quick Ratio	1.93	3.94	2.62	1.44	2.27	3.15	6.95	6.10	4.52	1.23	1.28
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	181	96	62	-569	175	-109	-6.45	-33	-28	-50	-29
Operating Cash Flow to CapEx	1,780.64%	1,020.04%	483.02%	274.10%	203.78%	694.16%	336.71%	92.31%	135.39%	69.54%	115.58%
Free Cash Flow to Firm to Interest Expense	117.91	1.76	1.54	-17.92	5.18	-4.61	-0.29	-1.51	-3.90	-6.44	-3.48
Operating Cash Flow to Interest Expense	123.54	2.86	3.63	3.96	2.28	2.98	2.23	0.82	4.74	3.60	3.21
Operating Cash Flow Less CapEx to Interest Expense	116.60	2.58	2.88	2.52	1.16	2.55	1.57	-0.07	1.24	-1.58	0.43
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.90	0.83	0.71	0.32	0.41	0.55	0.51	0.56	0.71	0.70	0.80
Accounts Receivable Turnover	12.81	13.24	13.70	7.25	8.54	9.85	9.68	9.31	9.91	10.33	10.70
Inventory Turnover	1.48	1.84	2.05	1.72	1.91	2.00	1.93	2.42	2.37	1.58	3.46
Fixed Asset Turnover	8.22	7.55	7.17	3.33	3.56	3.95	3.13	2.76	2.89	3.30	3.63
Accounts Payable Turnover	9.79	11.95	15.47	13.37	10.10	7.86	5.98	7.93	13.55	9.27	15.76
Days Sales Outstanding (DSO)	28.49	27.57	26.65	50.34	42.72	37.07	37.69	39.22	36.84	35.34	34.12
Days Inventory Outstanding (DIO)	245.90	198.06	178.21	212.36	191.24	182.76	189.09	150.89	154.02	230.95	105.63
Days Payable Outstanding (DPO)	37.30	30.55	23.59	27.29	36.13	46.46	61.00	46.02	26.93	39.37	23.16
Cash Conversion Cycle (CCC)	237.09	195.08	181.27	235.40	197.83	173.37	165.78	144.09	163.93	226.92	116.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	843	1,076	1,111	1,101	465	304	188	170	155	150	92
Invested Capital Turnover	1.46	1.23	1.21	0.69	1.12	1.71	1.88	1.76	1.81	2.06	2.50
Increase / (Decrease) in Invested Capital	-232	-36	10	636	161	116	18	15	5.11	58	25
Enterprise Value (EV)	935	1,772	2,106	3,051	2,445	1,840	1,636	1,743	1,144	2,754	3,117
Market Capitalization	870	1,567	1,769	2,680	2,600	1,890	1,769	1,852	1,208	2,823	3,197
Book Value per Share	$16.86	$18.74	$17.03	$16.40	$14.26	$8.51	$7.81	$6.89	$5.85	$5.94	$4.75
Tangible Book Value per Share	$7.63	$4.82	$1.56	($0.87)	$9.75	$3.62	$6.30	$5.53	$4.61	$5.10	$4.08
Total Capital	1,364	1,393	1,464	1,780	1,082	661	612	556	328	322	274
Total Debt	585	522	689	1,049	463	306	291	276	109	104	103
Total Long-Term Debt	384	514	656	675	313	306	291	276	109	0.00	0.00
Net Debt	65	205	336	371	-154	-51	-133	-109	-64	-68	-79
Capital Expenditures (CapEx)	11	15	30	46	38	10	15	19	25	40	23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	152	143	96	63	26	8.93	34	24	26	48	19
Debt-free Net Working Capital (DFNWC)	637	421	384	720	548	301	418	335	198	207	177
Net Working Capital (NWC)	435	413	351	345	398	301	417	335	198	103	74
Net Nonoperating Expense (NNE)	148	-24	40	25	190	18	12	25	16	6.42	10
Net Nonoperating Obligations (NNO)	65	205	336	371	-154	-51	-133	-109	-64	-68	-79
Total Depreciation and Amortization (D&A)	82	79	99	54	38	35	26	26	17	16	15
Debt-free, Cash-free Net Working Capital to Revenue	10.87%	10.57%	7.17%	11.67%	6.12%	2.12%	10.14%	8.33%	9.28%	19.22%	9.70%
Debt-free Net Working Capital to Revenue	45.44%	31.20%	28.81%	132.89%	127.53%	71.46%	123.83%	116.95%	71.73%	83.07%	89.72%
Net Working Capital to Revenue	31.04%	30.56%	26.29%	63.70%	92.70%	71.46%	123.73%	116.84%	71.73%	41.28%	37.56%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.15)	$0.91	$0.35	$0.95	$3.41	($0.27)	($0.01)	($1.07)	($1.02)	$0.05	($0.39)
Adjusted Weighted Average Basic Shares Outstanding	46.25M	46.22M	45.52M	44.26M	42.67M	42.03M	41.23M	39.81M	37.24M	36.54M	36.24M
Adjusted Diluted Earnings per Share	($2.15)	$0.89	$0.34	$0.92	$3.33	($0.27)	($0.01)	($1.07)	($1.02)	$0.04	($0.39)
Adjusted Weighted Average Diluted Shares Outstanding	46.25M	51.98M	46.54M	45.63M	43.68M	42.03M	41.23M	39.81M	37.24M	41.30M	36.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.27)	($0.01)	$0.00	$0.00	$0.00	($0.39)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.28M	46.50M	45.95M	44.85M	43.86M	41.51M	40.91M	40.71M	37.53M	37.05M	35.30M
Normalized Net Operating Profit after Tax (NOPAT)	177	60	42	67	36	25	12	-14	-22	8.28	-3.62
Normalized NOPAT Margin	12.64%	4.42%	3.15%	12.36%	8.39%	5.94%	3.63%	-4.90%	-8.11%	3.32%	-1.83%
Pre Tax Income Margin	-9.00%	9.14%	1.99%	10.42%	4.68%	-2.55%	-0.13%	-14.82%	-13.69%	0.85%	-6.85%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-41.41	1.14	0.05	2.75	1.46	0.23	0.68	-1.14	-4.55	1.19	-0.68
NOPAT to Interest Expense	-33.50	1.10	1.80	2.11	9.95	0.31	0.51	-0.80	-3.17	1.06	-0.44
EBIT Less CapEx to Interest Expense	-48.35	0.86	-0.70	1.30	0.34	-0.20	0.02	-2.02	-8.05	-4.00	-3.46
NOPAT Less CapEx to Interest Expense	-40.44	0.82	1.04	0.66	8.83	-0.12	-0.15	-1.69	-6.67	-4.12	-3.21
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-17.25%	1.39%	3.69%	10.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Pacira BioSciences' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	1.08%	3.74%	2.83%	5.05%	4.23%	2.08%	-2.11%	0.03%	1.49%	0.00%	0.00%
EBITDA Growth	-11.68%	111.97%	-425.28%	-19.42%	77.68%	212.17%	12.16%	11.97%	-53.78%	0.00%	-25.53%
EBIT Growth	-51.04%	352.93%	-907.27%	-28.80%	520.93%	113.64%	61.81%	29.49%	-117.96%	0.00%	-65.94%
NOPAT Growth	-87.35%	-25.55%	-942.66%	-46.28%	501.96%	435.42%	262.55%	-3.80%	-113.29%	0.00%	-131.13%
Net Income Growth	-46.41%	-224.98%	-1,421.29%	-26.69%	145.96%	1,050.77%	1,666.81%	29.62%	-386.12%	0.00%	0.00%
EPS Growth	-47.37%	-34.48%	-1,452.17%	-23.53%	144.19%	405.26%	1,250.00%	27.50%	-386.67%	0.00%	0.00%
Operating Cash Flow Growth	-27.78%	-30.37%	21.34%	22.38%	156.70%	13.20%	4.18%	45.94%	-37.85%	0.00%	-29.25%
Free Cash Flow Firm Growth	94.45%	321.65%	113.16%	7.20%	2,839.88%	445.23%	-314.97%	113.63%	100.53%	97.31%	2,761.92%
Invested Capital Growth	-18.08%	-21.58%	-22.02%	-6.84%	-7.85%	-3.23%	0.00%	-4.90%	-0.48%	0.93%	-100.00%
Revenue Q/Q Growth	-80.98%	426.90%	-5.31%	6.53%	-7.79%	422.32%	-3.27%	5.69%	-6.75%	400.86%	-1.15%
EBITDA Q/Q Growth	-50.15%	148.11%	-347.72%	48.68%	-39.13%	-26.17%	-38.63%	227.84%	-20.34%	-173.83%	-38.74%
EBIT Q/Q Growth	-81.70%	125.00%	-595.19%	116.05%	-61.25%	-55.44%	-56.32%	1,377.27%	68.40%	-628.80%	-65.05%
NOPAT Q/Q Growth	-93.64%	117.71%	-769.95%	67.62%	-64.45%	100.41%	-57.29%	1,354.33%	68.76%	2.88%	-125.28%
Net Income Q/Q Growth	105.76%	41.78%	-859.64%	110.34%	-63.90%	515.44%	-57.85%	231.87%	-93.39%	937.95%	-103.49%
EPS Q/Q Growth	-73.68%	112.22%	-897.44%	105.26%	-67.24%	152.17%	-54.90%	218.60%	-126.32%	-850.00%	-105.00%
Operating Cash Flow Q/Q Growth	7.02%	-38.55%	1.28%	8.42%	3.19%	7.08%	2.16%	127.41%	-54.50%	-1.45%	43.11%
Free Cash Flow Firm Q/Q Growth	-23.46%	76.48%	57.03%	-8.33%	62.57%	105.51%	-1,379.05%	2,414.11%	119.49%	-103.43%	181.10%
Invested Capital Q/Q Growth	2.00%	-0.35%	-17.65%	-2.11%	-2.37%	-0.91%	-1.62%	-3.18%	2.53%	0.00%	-100.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	79.69%	95.51%	76.95%	75.14%	71.63%	94.43%	75.75%	71.55%	69.43%	92.62%	69.74%
EBITDA Margin	16.83%	6.42%	-70.32%	26.88%	19.26%	3.14%	22.23%	35.04%	11.30%	-2.86%	19.40%
Operating Margin	1.18%	2.78%	-82.77%	15.86%	7.91%	3.87%	10.81%	23.53%	-1.93%	-1.18%	12.71%
EBIT Margin	3.78%	3.93%	-82.84%	15.84%	7.81%	0.90%	10.55%	23.37%	-1.93%	-6.74%	6.38%
Profit (Net Income) Margin	2.85%	-9.40%	-85.11%	10.61%	5.37%	7.80%	6.62%	15.20%	-12.18%	0.69%	-0.41%
Tax Burden Percent	55.27%	222.24%	103.32%	51.62%	65.83%	70.03%	65.41%	68.06%	73.79%	-121.84%	-33.49%
Interest Burden Percent	136.22%	-107.63%	99.43%	129.73%	104.50%	1,237.79%	95.97%	95.57%	853.72%	8.43%	19.35%
Effective Tax Rate	44.73%	0.00%	0.00%	48.38%	34.17%	29.97%	34.59%	31.94%	0.00%	0.00%	133.49%
Return on Invested Capital (ROIC)	0.96%	2.84%	-41.69%	5.31%	3.24%	3.35%	8.67%	9.47%	-0.79%	-1.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	4.34%	-71.71%	-67.81%	7.25%	3.35%	19.44%	8.10%	9.08%	-5.10%	2.61%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.56%	-11.76%	-15.04%	1.91%	1.07%	6.40%	2.47%	4.05%	-2.78%	1.22%	0.00%
Return on Equity (ROE)	1.52%	-8.92%	-56.72%	7.21%	4.31%	9.75%	11.14%	13.52%	-3.57%	0.23%	0.00%
Cash Return on Invested Capital (CROIC)	13.67%	18.84%	20.04%	12.56%	14.75%	8.74%	-194.21%	8.00%	2.90%	5.57%	200.00%
Operating Return on Assets (OROA)	3.35%	3.52%	-37.68%	6.86%	3.43%	0.75%	9.16%	9.55%	-0.76%	-4.79%	0.00%
Return on Assets (ROA)	2.52%	-8.43%	-38.71%	4.59%	2.36%	6.47%	5.75%	6.21%	-4.78%	0.49%	0.00%
Return on Common Equity (ROCE)	1.52%	-8.92%	-56.72%	7.21%	4.31%	9.75%	11.14%	13.52%	-3.57%	0.23%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-25.46%	0.00%	-12.10%	7.23%	7.90%	0.00%	0.84%	-0.57%	-1.36%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	1.10	17	-98	15	8.70	23	12	27	-2.16	-6.93	-7.13
NOPAT Margin	0.65%	1.95%	-57.94%	8.19%	5.20%	2.71%	7.07%	16.01%	-1.35%	-0.83%	-4.26%
Net Nonoperating Expense Percent (NNEP)	-3.38%	74.55%	26.12%	-1.94%	-0.11%	-16.09%	0.58%	0.39%	4.31%	-3.60%	6.07%
Return On Investment Capital (ROIC_SIMPLE)	0.08%	1.27%	-	-	-	1.67%	-	-	-	-0.47%	-
Cost of Revenue to Revenue	20.31%	4.49%	23.05%	24.86%	28.37%	5.57%	24.25%	28.45%	30.57%	7.38%	30.26%
SG&A Expenses to Revenue	51.37%	8.96%	44.10%	38.27%	43.10%	7.69%	41.45%	38.27%	44.18%	7.63%	36.59%
R&D to Revenue	15.00%	2.69%	11.33%	11.42%	10.91%	2.27%	12.71%	11.11%	10.69%	2.09%	11.59%
Operating Expenses to Revenue	78.51%	124.95%	159.71%	59.27%	63.72%	87.05%	64.94%	48.02%	71.36%	92.17%	57.03%
Earnings before Interest and Taxes (EBIT)	6.39	35	-140	28	13	7.71	17	40	-3.10	-57	11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	28	57	-119	48	32	27	36	59	18	-24	32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.44	1.12	0.93	1.51	1.52	1.80	1.71	2.28	2.44	2.28	0.00
Price to Tangible Book Value (P/TBV)	3.36	2.47	2.24	5.09	5.23	7.01	8.34	13.87	23.87	24.84	0.00
Price to Revenue (P/Rev)	0.82	0.62	1.00	1.93	1.99	1.16	2.14	2.75	2.80	1.33	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	20.94	19.28	167.68	203.93	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	4.78%	5.19%	0.60%	0.49%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.41	1.11	0.93	1.44	1.44	1.65	1.55	1.94	1.97	1.89	0.00
Enterprise Value to Revenue (EV/Rev)	0.86	0.67	1.14	2.14	2.22	1.31	2.52	3.19	3.36	1.58	0.00
Enterprise Value to EBITDA (EV/EBITDA)	82.04	50.46	55.02	8.74	8.38	12.58	12.28	16.11	17.78	20.91	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	16.05	14.63	28.81	38.14	57.19	79.21	1,045.54	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	25.35	21.07	29.73	53.39	63.39	81.18	29.33	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	6.89	4.94	3.88	7.62	8.21	11.46	11.25	14.51	16.81	14.49	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	9.28	5.17	4.09	11.06	9.39	18.55	0.00	23.61	67.71	34.20	4.81
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.73	0.75	0.78	0.67	0.58	0.60	0.63	0.68	0.72	0.89	0.00
Long-Term Debt to Equity	0.48	0.49	0.51	0.67	0.57	0.59	0.62	0.66	0.71	0.85	0.00
Financial Leverage	0.13	0.16	0.22	0.26	0.32	0.33	0.31	0.45	0.55	0.47	-0.30
Leverage Ratio	1.88	1.90	1.93	1.89	1.87	1.98	1.85	2.09	2.31	2.50	1.89
Compound Leverage Factor	2.55	-2.04	1.92	2.45	1.96	24.49	1.77	2.00	19.73	0.21	0.37
Debt to Total Capital	42.22%	42.92%	43.93%	40.13%	36.84%	37.52%	38.68%	40.58%	41.89%	47.08%	0.00%
Short-Term Debt to Total Capital	14.62%	14.80%	15.07%	0.00%	0.61%	0.62%	0.64%	1.43%	0.82%	2.30%	0.00%
Long-Term Debt to Total Capital	27.59%	28.13%	28.86%	40.13%	36.23%	36.90%	38.05%	39.14%	41.07%	44.78%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	57.79%	57.08%	56.07%	59.87%	63.16%	62.48%	61.32%	59.42%	58.11%	52.92%	0.00%
Debt to EBITDA	39.50	31.59	40.85	3.48	2.88	3.71	3.84	4.16	4.38	6.85	0.00
Net Debt to EBITDA	4.18	3.51	6.73	0.88	0.87	1.46	1.86	2.23	2.94	3.34	0.00
Long-Term Debt to EBITDA	25.82	20.70	26.84	3.48	2.83	3.65	3.78	4.01	4.30	6.51	0.00
Debt to NOPAT	-9.85	-11.40	-12.93	10.09	7.23	8.76	16.69	16.36	20.01	9.60	0.00
Net Debt to NOPAT	-1.04	-1.27	-2.13	2.54	2.19	3.45	8.08	8.76	13.42	4.69	0.00
Long-Term Debt to NOPAT	-6.44	-7.47	-8.49	10.09	7.11	8.62	16.42	15.78	19.62	9.14	0.00
Altman Z-Score	1.93	1.80	0.79	1.84	1.89	2.43	1.84	2.14	1.99	1.98	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.41	2.40	2.25	6.82	5.81	5.24	4.78	3.94	3.81	3.37	0.00
Quick Ratio	1.90	1.93	1.81	5.49	4.58	3.94	3.55	2.94	2.71	2.62	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	191	249	141	90	98	59	-1,074	84	3.34	-17	500
Operating Cash Flow to CapEx	414.82%	1,564.31%	1,317.69%	3,348.18%	1,731.35%	2,646.50%	1,309.31%	1,277.88%	291.36%	765.42%	823.28%
Free Cash Flow to Firm to Interest Expense	41.68	0.00	30.14	0.00	29.61	2.91	-309.99	21.72	0.13	-1.55	50.68
Operating Cash Flow to Interest Expense	7.74	0.00	11.50	0.00	14.81	2.34	12.83	11.25	0.72	3.81	4.33
Operating Cash Flow Less CapEx to Interest Expense	5.88	0.00	10.63	0.00	13.95	2.25	11.85	10.37	0.47	3.31	3.80
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.89	0.90	0.45	0.43	0.44	0.83	0.87	0.41	0.39	0.71	0.00
Accounts Receivable Turnover	13.60	12.81	7.03	6.77	7.00	13.24	0.00	7.04	7.22	13.70	0.00
Inventory Turnover	1.36	1.48	1.71	1.83	1.93	1.84	0.00	2.18	2.16	2.05	0.00
Fixed Asset Turnover	8.35	8.22	4.06	3.95	3.86	7.55	0.00	3.60	3.60	7.17	0.00
Accounts Payable Turnover	9.79	9.79	9.94	8.34	13.95	11.95	0.00	10.99	13.22	15.47	0.00
Days Sales Outstanding (DSO)	26.83	28.49	51.89	53.89	52.16	27.57	0.00	51.86	50.54	26.65	0.00
Days Inventory Outstanding (DIO)	267.44	245.90	213.37	199.26	189.17	198.06	0.00	167.62	169.08	178.21	0.00
Days Payable Outstanding (DPO)	37.30	37.30	36.74	43.75	26.16	30.55	0.00	33.22	27.61	23.59	0.00
Cash Conversion Cycle (CCC)	256.97	237.09	228.53	209.41	215.17	195.08	0.00	186.27	192.02	181.27	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	860	843	846	1,028	1,050	1,076	1,085	1,103	1,140	1,111	0.00
Invested Capital Turnover	1.47	1.46	0.72	0.65	0.62	1.23	1.23	0.59	0.59	1.21	0.00
Increase / (Decrease) in Invested Capital	-190	-232	-239	-75	-89	-36	1,085	-57	-5.50	10	-507
Enterprise Value (EV)	1,212	935	791	1,480	1,517	1,772	1,678	2,138	2,247	2,106	2,437
Market Capitalization	1,150	870	694	1,332	1,359	1,567	1,424	1,843	1,875	1,769	2,437
Book Value per Share	$17.26	$16.86	$16.25	$18.89	$19.19	$18.74	$17.91	$17.57	$16.71	$17.03	$0.00
Tangible Book Value per Share	$7.39	$7.63	$6.71	$5.62	$5.59	$4.82	$3.68	$2.89	$1.71	$1.56	$0.00
Total Capital	1,382	1,364	1,337	1,469	1,412	1,393	1,356	1,360	1,322	1,464	0.00
Total Debt	583	585	587	589	520	522	525	552	554	689	0.00
Total Long-Term Debt	381	384	386	589	512	514	516	532	543	656	0.00
Net Debt	62	65	97	149	158	205	254	295	371	336	0.00
Capital Expenditures (CapEx)	8.55	2.12	4.09	1.59	2.84	1.80	3.39	3.40	6.57	5.49	5.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	154	152	131	135	132	143	127	119	114	96	0.00
Debt-free Net Working Capital (DFNWC)	647	637	585	540	458	421	362	340	288	384	0.00
Net Working Capital (NWC)	445	435	384	540	450	413	354	320	277	351	0.00
Net Nonoperating Expense (NNE)	-3.71	101	46	-4.31	-0.28	-44	0.73	1.38	17	-13	-6.44
Net Nonoperating Obligations (NNO)	62	65	97	149	158	205	254	295	371	336	0.00
Total Depreciation and Amortization (D&A)	22	22	21	20	19	19	19	20	21	33	22
Debt-free, Cash-free Net Working Capital to Revenue	10.95%	10.87%	18.88%	19.60%	19.42%	10.57%	19.09%	17.80%	17.08%	7.17%	0.00%
Debt-free Net Working Capital to Revenue	46.11%	45.44%	84.18%	78.16%	67.23%	31.20%	54.42%	50.79%	43.08%	28.81%	0.00%
Net Working Capital to Revenue	31.72%	31.04%	55.19%	78.16%	65.96%	30.56%	53.12%	47.88%	41.46%	26.29%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.10	$0.36	($3.11)	$0.41	$0.19	$0.55	$0.23	$0.56	($0.43)	($0.22)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	46.28M	46.25M	46.13M	46.17M	46.50M	46.22M	46.42M	46.09M	45.95M	45.52M	0.00
Adjusted Diluted Earnings per Share	$0.10	$0.38	($3.11)	$0.39	$0.19	$0.58	$0.23	$0.51	($0.43)	($0.19)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	46.53M	46.25M	46.13M	50.54M	52.19M	51.98M	52.07M	52.05M	45.95M	46.54M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.30M	46.28M	46.17M	46.13M	46.55M	46.50M	46.44M	46.42M	45.99M	45.95M	0.00
Normalized Net Operating Profit after Tax (NOPAT)	4.52	17	15	16	9.95	23	14	16	6.31	-6.93	15
Normalized NOPAT Margin	2.68%	1.95%	9.11%	8.98%	5.95%	2.71%	8.41%	9.34%	3.94%	-0.83%	9.10%
Pre Tax Income Margin	5.15%	-4.23%	-82.37%	20.55%	8.16%	11.14%	10.13%	22.34%	-16.51%	-0.57%	1.24%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.40	0.00	-29.78	0.00	3.94	0.38	4.99	10.25	-0.12	-5.12	1.08
NOPAT to Interest Expense	0.24	0.00	-20.83	0.00	2.62	1.14	3.35	7.02	-0.08	-0.63	-0.72
EBIT Less CapEx to Interest Expense	-0.47	0.00	-30.65	0.00	3.08	0.29	4.01	9.37	-0.36	-5.62	0.56
NOPAT Less CapEx to Interest Expense	-1.63	0.00	-21.70	0.00	1.77	1.05	2.37	6.14	-0.33	-1.12	-1.25
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-17.25%	-37.86%	54.02%	0.00%	1.39%	33.48%	-51.18%	-22.36%	3.69%	0.00%

Frequently Asked Questions About Pacira BioSciences' Financials

When does Pacira BioSciences's financial year end?

According to the most recent income statement we have on file, Pacira BioSciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Pacira BioSciences' net income changed over the last 10 years?

Pacira BioSciences' net income appears to be on a downward trend, with a most recent value of -$199.12 million in 2024, rising from -$13.72 million in 2014. The previous period was $83.91 million in 2023. See where experts think Pacira BioSciences is headed by visiting Pacira BioSciences' forecast page.

What is Pacira BioSciences's operating income?

Pacira BioSciences's total operating income in 2024 was -$73.37 million, based on the following breakdown:

Total Gross Profit: $1.23 billion
Total Operating Expenses: $1.59 billion

How has Pacira BioSciences revenue changed over the last 10 years?

Over the last 10 years, Pacira BioSciences' total revenue changed from $197.67 million in 2014 to $1.40 billion in 2024, a change of 609.2%.

How much debt does Pacira BioSciences have?

Pacira BioSciences' total liabilities were at $775.17 million at the end of 2024, a 10.1% increase from 2023, and a 400.3% increase since 2014.

How much cash does Pacira BioSciences have?

In the past 10 years, Pacira BioSciences' cash and equivalents has ranged from $35.94 million in 2016 to $585.58 million in 2021, and is currently $276.77 million as of their latest financial filing in 2024.

How has Pacira BioSciences' book value per share changed over the last 10 years?

Over the last 10 years, Pacira BioSciences' book value per share changed from 4.75 in 2014 to 16.86 in 2024, a change of 255.1%.

Related Companies

This page (NASDAQ:PCRX) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacira BioSciences (PCRX) Financials

Frequently Asked Questions About Pacira BioSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacira BioSciences (PCRX) Financials

Annual Income Statements for Pacira BioSciences

Quarterly Income Statements for Pacira BioSciences

Annual Cash Flow Statements for Pacira BioSciences

Quarterly Cash Flow Statements for Pacira BioSciences

Annual Balance Sheets for Pacira BioSciences

Quarterly Balance Sheets for Pacira BioSciences

Annual Metrics And Ratios for Pacira BioSciences

Quarterly Metrics And Ratios for Pacira BioSciences

Frequently Asked Questions About Pacira BioSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools